Press Releases.

Focused on three exclusive microRNA targets

- Japan Patent Office Joins Australian, European and U.S. Patent Offices in Granting Claims for Therapeutic Use of Inhibiting microRNA-122 for HCV Treatment

-New study published in Science Translational Medicine demonstrates microRNA-21 contributes to fibrogenesis in the kidney

-New Pre-clinical Data to be Presented on Proprietary Therapeutic Programs in Metabolic Disease and Cancer at Keystone Symposium and AACR Special Conference

-Regulus, Accelerate Brain Cancer Cure (ABC2) and Samsung Medical Center to Advance microRNA Therapeutics for Glioblastoma -

-Regulus Scientists to Provide Update on Lead Therapeutic Program at American Society of Nephrology Meeting-

-The Australia Patent Office Joins the U.S. and European Patent Offices in Granting Claims for Inhibiting microRNA-122 to Reduce Viral Load-

Speakers to Include NYU Langone Medical Center's Kathryn Moore, Ph.D., Who will Cover Research Findings Published Last Week in Nature

Speakers to Include NYU Langone Medical Center's Kathryn Moore, Ph.D., Who will Cover Research Findings Published Last Week in Nature

- New publication in Nature shows therapeutic silencing of microRNA-33a/b for atherosclerosis -

-Regulus Chief Scientific Officer to Provide Updates on Lead Therapeutic Programs Targeting microRNA-33 and microRNA-21 at Oligonucleotide Therapeutics Society Meeting-

- Professor and Howard Hughes Medical Institute Investigator at Cold Spring Harbor Laboratory known for the molecular elucidation of small regulatory RNAs -

- Work of scientists with Regulus, Alnylam and ETH Zurich shows microRNAs 103/107 are upregulated in mouse models of obesity; targeting with anti-miRs improves glucose homeostasis and insulin sensitivity -

- Paper published in Journal of Clinical Investigation supports development of anti-microRNA 33 as potential therapeutic for atherosclerosis and related metabolic diseases -